# Diabetes Research Hub — Monitor Review

**Run date:** 2026-06-17 (automated, scheduled)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot diffs, and a 7-day web scan.
**Mode:** Read-only review. No source files were modified.

---

## Headline (read this first)

**The FDA approved a new pediatric Tzield (teplizumab) indication on June 12, 2026** — accelerated approval to delay C-peptide decline in children 8–17 recently diagnosed with Stage 3 T1D, based on the Phase 3 PROTECT study. This is the single most actionable item this cycle. Our own PubMed tracker independently surfaced a cluster of teplizumab papers in the same window (efficacy meta-analysis, CGM response monitoring, MS/T1D shared-pathway work), so the literature and the regulatory action are converging. **Action: log the approval in the tracker and review the teplizumab paper cluster.** `[Certain]` — confirmed via FDA press release.

Everything else is incremental. Day-over-day the data is essentially flat (0 trial changes); the meaningful movement is week-over-week and is dominated by the ADA 86th Scientific Sessions (June 5–8) publication surge.

---

## File System Status

| File | Last modified | State |
|------|---------------|-------|
| `clinical_trials_latest.json` | 2026-06-17 07:06 | Fresh |
| `pubmed_recent_latest.json` | 2026-06-17 07:06 | Fresh |
| `hub_monitor_report.md` | 2026-06-17 07:06 | Fresh |
| `literature_gap_report.md` | 2026-06-16 21:12 | Report fresh, but built on **stale data** |
| `literature_gap_data.json` | 2026-04-20 | **Stale (~58 days)** |

The hub monitor flags **720 result files older than 14 days**. Most are dated daily snapshots that are fine to retain. The one that matters: the gap analysis report was regenerated on 2026-06-16 but its underlying data (`literature_gap_data.json`) and PubMed query window still end **2026/04/20**. The rankings are therefore ~2 months old. `[Certain]`

Trackers `Diabetes_Research_Tracker.xlsx` (Apr 17) and `literature_gap_matrix.xlsx` (Apr 20) have not been touched in ~2 months.

---

## Clinical Trial Changes

**Totals:** 813 unique trials. 261 RECRUITING, 141 NOT_YET_RECRUITING, 295 COMPLETED. 123 are Phase 3.

**Day-over-day (06-16 → 06-17):** 0 new, 0 removed, 0 status changes, 0 new results. `[Certain]`

**Week-over-week (06-10 → 06-17):** +10 new, −3 removed, 2 status changes, 0 new results posted. The 10 new registrations are routine (device accuracy studies, vagus-nerve stimulation, an ESG/bariatric study, a Steno AID-vs-injections trial, plus two completed-with-results dietary studies that newly entered the results category). None are Phase 3 cure/immunotherapy. Two trials moved RECRUITING → ACTIVE_NOT_RECRUITING (NCT05000021 diabetes-distress CBT; NCT05696366 combination adjunctive therapy). `[Certain]`

**Phase 3 trials to keep watching (recruiting / active):**

- **VX-880 (Vertex), NCT06832410 & NCT04786262** — Phase 3, RECRUITING. Stem-cell-derived islet therapy; the flagship T1D cure program.
- **Baricitinib (Lilly), NCT07222332 & NCT07222137** — Phase 3, RECRUITING. Beta-cell preservation and Stage-3 delay in T1D. Directly relevant given baricitinib is on our key-therapy watch list.
- **Teplizumab (Sanofi), NCT07088068** — Phase 3, RECRUITING. Now reading against this week's FDA pediatric approval.
- **Cadisegliatin / glucokinase activator (vTv), NCT06334133** — Phase 3, RECRUITING. Adjunct-to-insulin in T1D; the only GKA Phase 3 in the set and relevant to multiple Tier-1 gap intersections below.
- **Dimethyl fumarate (Nanjing Medical), NCT07258394 & NCT07548996** — Phase 3 / 2-3, islet-β preservation in T1D. A repurposing signal worth noting.
- **Icodec weekly insulin / CagriSema (Novo Nordisk), NCT07076199, NCT07564414, NCT07282613** — Phase 3, active.

No new results were posted to ClinicalTrials.gov in the past week, but results posted earlier in June worth a look include **NCT04426474 (Lilly, orforglipron in T2D, posted 05-26)** and two Novo weekly-insulin studies (**NCT05813912**, posted 06-03).

---

## PubMed Highlights

168 unique papers in the 30-day window across 16 alert domains. Day-over-day: **12 new papers, 10 dropped.** `[Certain]`

**Cross-domain papers (highest value — appear in ≥2 domains):**

1. **PMID 42294227** — *Liraglutide and Dapagliflozin Synergistically Reshape Gut Microbiota and Metabolic Profiles* (Biomarker + Microbiome + Multi-Omics + dapagliflozin). 4-domain hit; directly in the Multi-Omics Tier-1 lane.
2. **PMID 42296503** — *Benefits and Harms of Pharmacologic Treatments in Overweight/Obesity: Living Systematic Review* (orforglipron + retatrutide).
3. **PMID 42297781** — *Multi-omics reveals microbiota/metabolite/immunological heterogeneity* (Microbiome + Multi-Omics).
4. **PMID 42269843** / **42267680** — Two teplizumab papers (T1D Immunotherapy): MS/T1D shared immune pathways, and CGM-based teplizumab response assessment.

**Key-therapy activity (this is where the volume is):** The early-June ADA Scientific Sessions drove a heavy incretin publication wave —

- **Orforglipron:** 5+ papers including ACHIEVE-5 (added to insulin glargine) and a head-to-head vs dapagliflozin.
- **CagriSema:** the REIMAGINE program (REIMAGINE 2/3, renal/hepatic PK) — 5 papers.
- **Retatrutide:** Phase 3 efficacy/safety in T2D plus multisystem-benefit reviews.
- **Icodec (weekly insulin):** 5 papers on weekly-vs-daily basal insulin.
- **Teplizumab:** efficacy meta-analysis for Stage 3 T1D + the two cross-domain hits above.

**New this cycle worth a glance:** PMID 41729594 — *Semaglutide as add-on therapy in LADA* (JCEM). LADA is a Tier-1-adjacent gap domain (see below), and a named-therapy LADA paper is rare. `[Likely]` worth tracking.

**Volume read:** activity is concentrated in incretins/GLP-1 and microbiome; the genuinely under-published domains in our own gap data (LADA, Drug Repurposing, Glucokinase, Beta Cell Regen, Treg/CAR-T) remain quiet — consistent with the gaps below.

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score, joint pubs) — **Validation level: BRONZE** (single analytical source; expert confirmation required per the Doctrine):

1. **Beta Cell Regen × Health Equity** — 100.0 (0 joint pubs)
2. **Insulin Resistance × Islet Transplant** — 100.0 (1)
3. **Islet Transplant × Drug Repurposing** — 100.0 (0)
4. **Islet Transplant × Health Equity** — 100.0 (0)
5. **Gene Therapy × LADA** — 100.0 (0)

**Alignment with our Tier-1 contribution areas** (Multi-Omics, Lit Synthesis/Gap, Clinical Trial Intelligence, Drug Repurposing, AI/ML, Epi/Health Equity):

- **Drug Repurposing intersections** (#3 Islet Transplant × Drug Repurposing; also Glucokinase × Drug Repurposing, Drug Repurposing × LADA) map directly onto Tier-1 Area #4. The vTv cadisegliatin Phase 3 and the dimethyl-fumarate T1D trials above are real-world anchors that make these gaps tractable rather than purely theoretical.
- **Health Equity intersections** (#1, #4, plus Treg/CAR-T × Equity) map onto Tier-1 Area #6 (Gap score 4 — explicitly under-resourced in the Doctrine).
- **Multi-Omics**: PMID 42294227 and 42297781 are live examples of the cross-omics work Tier-1 Area #1 targets.

**Caveat:** these rankings sit on Apr-20 data. Before acting on any single gap, re-run the analysis (below) — two months of incretin/teplizumab literature has accumulated since.

---

## Breaking News (7-day web scan)

- **FDA — Tzield (teplizumab) pediatric Stage 3 T1D approval, June 12, 2026.** Significant; detailed above. `[Certain]`
- **FDA — Sanofi diabetes drug cleared in newly diagnosed pediatric patients, early June 2026.** `[Likely]` — appeared in search; corroborate against the Sanofi teplizumab Phase 3 (NCT07088068) before logging.
- **Applied Biologics BIOxHEAL — FDA IND clearance into Phase 3 for diabetic foot ulcers, June 9, 2026.** Minor; note only. `[Likely]`
- **ADA 86th Scientific Sessions, June 5–8, New Orleans** — explains this cycle's incretin publication surge. Context, not an action item. `[Certain]`

Nothing else in the window rose above routine.

---

## Recommended Actions

1. **Log the Tzield pediatric approval (06-12-2026)** in `Diabetes_Research_Tracker.xlsx` under T1D Immunotherapy; tag evidence as `[Certain]` (FDA press release primary source). Highest priority.
2. **Re-run gap analysis — data is ~58 days stale.** `python project1_literature_gap_analysis.py` to refresh `literature_gap_data.json` past the 2026/04/20 cutoff before treating any ranking as current.
3. **Review the teplizumab cross-domain cluster** (PMID 42269843, 42267680, 42221148) against the new approval — this is the convergence point this cycle.
4. **Verify the Sanofi pediatric item** against NCT07088068 before adding it to the tracker (avoid double-counting with the BMS/Tzield approval).
5. **Add notable Phase 3 trials to the `clinical_trials_summary.md` watch table** (currently empty): VX-880 (NCT06832410), Lilly baricitinib (NCT07222332/137), vTv cadisegliatin (NCT06334133). The script leaves this for manual curation.
6. **Flag PMID 41729594 (semaglutide in LADA)** for the LADA gap workstream — rare named-therapy LADA evidence.

---

*Generated by the Diabetes Hub scheduled monitor. Read-only review run — no existing files modified. Claims labeled with confidence per RESEARCH_DOCTRINE.md; gap classifications remain BRONZE pending expert validation.*
